Aegerion To Admit Guilt, Pay $40M Over Drug Marketing
Aegerion Pharmaceuticals said Thursday it expects to plead guilty to two misdemeanors, pay $40 million and enter into multiple settlements related to alleged violations of drug marketing requirements, securities law and...To view the full article, register now.
Already a subscriber? Click here to view full article